United Homes Group stock plunges after Nikki Haley, directors resign
NEW YORK - Johnson & Johnson (NYSE:JNJ) announced Tuesday that its Board of Directors has declared a quarterly cash dividend of $1.30 per share on the company’s common stock for the fourth quarter of 2025.
The dividend will be payable on December 9, 2025, to shareholders of record at the close of business on November 25, 2025, according to a press release statement from the healthcare company. The ex-dividend date is also set for November 25, 2025.
Johnson & Johnson, a major player in the healthcare sector, focuses on innovative medicine and medical technology. The company operates across multiple healthcare segments, developing treatments and solutions for various medical conditions.
The quarterly dividend announcement represents a routine financial action for the company, which regularly provides dividend payments to its shareholders.
In other recent news, Johnson & Johnson announced plans to separate its orthopaedics business into a standalone entity named DePuy Synthes. This move, expected to be completed within 18 to 24 months, aims to enhance strategic focus for Johnson & Johnson, allowing it to concentrate on its key growth areas in Innovative Medicine and MedTech. Meanwhile, Johnson & Johnson faces a significant legal setback as a Los Angeles jury ordered the company to pay $966 million in a baby powder case linked to mesothelioma. In the realm of analyst updates, Goldman Sachs raised its price target for Johnson & Johnson to $212, maintaining a Conviction Buy rating due to strong performance in the Innovative Medicines segment. The firm anticipates the company will exceed consensus estimates for key products in its upcoming third-quarter earnings report. Guggenheim also reiterated its Buy rating with a $206 price target on Johnson & Johnson stock, noting positive investor reception. Additionally, BMO Capital increased the price target for Protagonist Therapeutics to $112, following reports of a potential acquisition by Johnson & Johnson. These developments highlight a dynamic period for Johnson & Johnson, with strategic, legal, and market factors all in play.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.